Drug details
Zytiga (abiraterone acetate tablets)
type of Antineoplastics, Antiandrogen, Antiandrogens
Zytiga (abiraterone acetate) is is an inhibitor of CYP17 (17a-hydroxylase/C17,20-lyase) given in combination with prednisone and indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
The drug is often used to treat Prostate cancer .
This drug may have the following side effects:
- cough
- diarrhea
- vomiting
- sweating
- anemia
- shortness of breath
- weakness
- urinary tract infection
- high blood pressure
- bruising
- low blood potassium
- hot flashes
- joint swelling or pain
- swelling in your legs or feet
- high blood sugar levels
- high blood cholesterol and triglycerides
The following drugs are related to Zytiga, either as a replacement or used together:
- Casodex (bicalutamide)
- Camcevi (leuprolide mesylate injectable emulsion)
- Eligard (leuprolide acetate)
- Emcyt (estramustine)
- Eulexin (flutamide)
- Zoladex 10.8 mg (goserelin acetate implant)
- Lupron Depot 11.25 mg (leuprolide acetate for depot suspension)
- Lupron Depot 7.5 mg (leuprolide acetate for depot suspension)
- Lupron Depot (leuprolide acetate for depot suspension)
- Lutrate Depot (leuprolide acetate for depot suspension)
- Lupron Depot 22.5 (leuprolide acetate for depot suspension injection)
- Lupron (leuprolide acetate injection)
- Lupron Depot 3.75 mg (leuprolide acetate injection)
- Pluvicto (lutetium lu 177 vipivotide tetraxetan)
- Nilandron (nilutamide tablets)
- Tazverik (tazemetostat tablets)
- Trelstar (triptorelin pamoate for injectable suspension)
- Trelstar Depot (triptorelin pamoate for injectable suspension)
- Trelstar LA (triptorelin pamoate for injectable suspension)